SGMT
Sagimet Biosciences Inc. - Seri
$7.71
+0.92%
2026-05-08
About Sagimet Biosciences Inc. - Seri
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Key Fundamentals
Forward P/E
-5.16
EPS (TTM)
$-1.58
ROE
-38.2%
Profit Margin
0.0%
Debt/Equity
0.07
Price/Book
2.22
Beta
3.64
Market Cap
$469.9M
Avg Volume (10D)
6.4M
Recent Breakout Signals
No recent breakout signals detected for SGMT.
Recent Price Range (60 Days)
60D High
$9.37
60D Low
$4.50
Avg Volume
1.4M
Latest Close
$7.71
Get breakout alerts for SGMT
Sign up for Breakout Scanner to receive daily notifications when SGMT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Sagimet Biosciences Inc. - Seri (SGMT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SGMT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SGMT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.